Treatment strategies for imipenemase-producing Gram-negative infections: lessons from Japan
The Lancet Microbe · 2026-09 · 7 (9) · 101413
DOI: 10.1016/j.lanmic.2026.101413 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Lancet Microbe, 2026-09. Verfasst von Daisuke Ono und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases and Infection Control, Saitama Medical Center, Saitama Medical University, Saitama, Japan. Hauptthemen laut MEDLINE: Gram-Negative Bacterial Infections, Anti-Bacterial Agents, beta-Lactamases, Bacterial Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Carbapenems remain essential for treating serious infections caused by drug-resistant Gram-negative bacteria because of their broad-spectrum activities and favourable safety profiles. However, the emergence of carbapenemase-producing Enterobacterales, which produce enzymes that efficiently hydrolyse β-lactams including carbapenems, continues to undermine their clinical utility. Although new antibiotics such as ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, and cefiderocol have expanded therapeutic options, their effectiveness varies substantially across different carbapenemase families. Carbapenemases produced by Enterobacterales include serine β-lactamases (Ambler classes A and D) and metallo-β-lactamases (MBLs; Ambler class B), each with distinct substrate and inhibitor profiles. Clinically relevant MBLs-including imipenemase (IMP), New Delhi MBL (NDM), and Verona integron-encoded MBL (VIM) variants-show markedly different biochemical properties and inhibitor susceptibilities. Despite their clinical relevance, optimal treatment strategies for infections caused by IMP-producing Enterobacterales remain poorly defined. The unique reactivity of IMP-type MBLs to inhibitors differs from that of other MBLs such as NDMs or VIMs, underscoring the need for tailored therapeutic approaches. In this Personal View, we summarise current evidence and, drawing on Japan's experience as an endemic setting for IMP producers, outline key scientific, clinical, and public health challenges that should be addressed globally to develop effective, evidence-based treatment strategies for IMP-producing Enterobacterales infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases and Infection Control, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
- Department of Microbiology and Infectious Diseases, Toho University School of Medicine, Tokyo, Japan.
- Department of Microbial Genomics and Ecology, The Center for Planetary Health and Innovation Science (PHIS), The IDEC Institute, Hiroshima University, Hiroshima, Japan.
- Department of Molecular Biology and Microbiology, School of Medicine, Case Western Reserve University, Cleveland, OH, USA; Research Service, Veterans Affairs Northeast Ohio Healthcare System, Cleveland, OH, USA; CWRU-Cl…
- Research Service, Veterans Affairs Northeast Ohio Healthcare System, Cleveland, OH, USA; Department of Medicine, Department of Pharmacology, Department of Molecular Biology and Microbiology, Department of Biochemistry,…
Zitieren
APA
Ono, D., Harada, S., Ishii, Y., Mojica, M. F., & Bonomo, R. A. (2026). Treatment strategies for imipenemase-producing Gram-negative infections: lessons from Japan. The Lancet Microbe, 7(9), 101413. https://doi.org/10.1016/j.lanmic.2026.101413
Vancouver
Ono D, Harada S, Ishii Y, Mojica MF, Bonomo RA. Treatment strategies for imipenemase-producing Gram-negative infections: lessons from Japan. The Lancet Microbe. 2026;7(9):101413. doi:10.1016/j.lanmic.2026.101413
BibTeX
@article{Ono2026,
author = {Ono, Daisuke and Harada, Sohei and Ishii, Yoshikazu and Mojica, Maria F and Bonomo, Robert A},
title = {Treatment strategies for imipenemase-producing Gram-negative infections: lessons from Japan},
journal = {The Lancet Microbe},
year = {2026},
volume = {7},
number = {9},
pages = {101413},
doi = {10.1016/j.lanmic.2026.101413}
}
EUVIMED